Giana Kristy Ramos1,2, David S Goldfarb3,4. 1. Nephrology Division, NYU Langone Health, New York, NY, USA. 2. New York Harbor VA Healthcare System, New York, NY, USA. 3. Nephrology Division, NYU Langone Health, New York, NY, USA. david.goldfarb@nyulangone.org. 4. New York Harbor VA Healthcare System, New York, NY, USA. david.goldfarb@nyulangone.org.
Abstract
PURPOSE OF REVIEW: In this review, we report on new findings regarding associations of uric acid with kidney health. We discuss kidney stones, effects of uric acid in chronic kidney disease (CKD), and management of gout in CKD. Recent studies on neuroprotective effects of raising uric acid provide interesting data regarding nephrolithiasis. RECENT FINDINGS: Elevated urate levels have been implicated in the progression of chronic kidney disease (CKD), but the results from PERL and CKD-FIX studies did not demonstrate that allopurinol slowed CKD progression. The SURE-PD3 sought to determine if increasing uric acid would slow the progression of Parkinson's disease. Results ultimately did not support this hypothesis, but high urinary uric acid levels caused uric acid stones, not calcium stones. Low urinary pH remains the key to the formation of uric acid stones. Thiazolidinediones improve insulin resistance, which is associated with an increase in urine pH. The most recent research has not supported the hypothesis that lowering serum uric acid levels will slow the progression of CKD or provide neuroprotection in Parkinson's disease. It is still unclear as to why uric acid stone formers have a high net acid excretion. The STOP-GOUT trial demonstrates that there was a lack of significant adverse events with higher urate-lowering dosages of allopurinol and febuxostat, despite patients' kidney function. This may push other studies to administer higher dosages per ACR guidelines. Future studies could then demonstrate decreased progression of CKD.
PURPOSE OF REVIEW: In this review, we report on new findings regarding associations of uric acid with kidney health. We discuss kidney stones, effects of uric acid in chronic kidney disease (CKD), and management of gout in CKD. Recent studies on neuroprotective effects of raising uric acid provide interesting data regarding nephrolithiasis. RECENT FINDINGS: Elevated urate levels have been implicated in the progression of chronic kidney disease (CKD), but the results from PERL and CKD-FIX studies did not demonstrate that allopurinol slowed CKD progression. The SURE-PD3 sought to determine if increasing uric acid would slow the progression of Parkinson's disease. Results ultimately did not support this hypothesis, but high urinary uric acid levels caused uric acid stones, not calcium stones. Low urinary pH remains the key to the formation of uric acid stones. Thiazolidinediones improve insulin resistance, which is associated with an increase in urine pH. The most recent research has not supported the hypothesis that lowering serum uric acid levels will slow the progression of CKD or provide neuroprotection in Parkinson's disease. It is still unclear as to why uric acid stone formers have a high net acid excretion. The STOP-GOUT trial demonstrates that there was a lack of significant adverse events with higher urate-lowering dosages of allopurinol and febuxostat, despite patients' kidney function. This may push other studies to administer higher dosages per ACR guidelines. Future studies could then demonstrate decreased progression of CKD.
Authors: Angelo L Gaffo; David A Calhoun; Elizabeth J Rahn; Suzanne Oparil; Peng Li; Tanja Dudenbostel; Daniel I Feig; David T Redden; Paul Muntner; Phillip J Foster; Stephanie R Biggers-Clark; Amy Mudano; Sebastian E Sattui; Michael B Saddekni; S Louis Bridges; Kenneth G Saag Journal: Arthritis Rheumatol Date: 2021-06-05 Impact factor: 10.995
Authors: Isobel Sleeman; Rachael A Lawson; Alison J Yarnall; Gordon W Duncan; Fionnuala Johnston; Tien K Khoo; David J Burn Journal: J Parkinsons Dis Date: 2019 Impact factor: 5.520